echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Cell Death Differ: EZH2 R342 methylation modification promotes breast cancer metastasis.

    Cell Death Differ: EZH2 R342 methylation modification promotes breast cancer metastasis.

    • Last Update: 2020-09-24
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    EZH2 is a key histoprotein methyl transferase and EMT-inducing factor that previous studies have found to be expressed in a variety of cancers, including breast cancer, and is an important cancer-causing gene.
    EZH2 is able to catalyz the trimethylation modification (H3K27me3) of lysine 3 through its SET domain and inhibit transcription of its target gene, ultimately promoting the EMT (endothoste-interstate transformation) process of cancer cells and tumor metastasis.
    the molecular mechanism of EZH2 disorder in cancer has yet to be studied.
    study, researchers found that the R342 bits of EZH2 were able to be asymmetrically modified by PRZH1 (meR342-EZH2).
    and meR342-EZH2 inhibit the phosphorylation modification of CDK1 to T345 and T487 bits, thereby reducing the EZH2 ubibinization process induced by E3 connective enzyme TRAF6.
    researchers also found that meR342-EZH2 can lead to lower levels of target gene expression in EZH2 and improve EMT processes, cell invasion, and tumor metastasis in breast cancer cells.
    , there was a positive correlation between the expression levels of PRMT1, meR342-EZH2 and EZH2 in breast cancer tissue.
    high levels of meR342-EZH2 also eventually corresponded to a poor clinical prognostic prognosticity in breast cancer patients.
    , the results provide a new diagnostic target and potential therapeutic target for breast cancer metastasis.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.